Mirikizumab Real World Protocol

Recruiting now

Conditions studied: Ulcerative Colitis

In brief

The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 year.

Key facts

Study ID

NCT06696014

Run by

University of North Carolina, Chapel Hill

People needed

100

Starts

2025-05-08

Expected to finish

2030-01-01

Last updated by the study team

2025-07-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients, age 18 years or older, with UC, who within 2 weeks have been started on mirikizumab therapy for moderate to severe UC or who plan to begin this therapy within the next 2 weeks. The start of the mirikizumab treatment must have been or be initiated in the setting of standard-of-care therapy.
• Anticipation that the patient will be followed by the participating center for the next 12 months.
• Diagnosis of UC must be established based on standard clinical, radiographic, endoscopic, and histologic criteria as described below.
• Criteria for diagnosis of UC The following diagnostic criteria were developed by the NIDDK IBD Genetics Consortium and are provided as guidelines to complete documentation on individuals with Ulcerative Colitis.
• A) Symptoms including one or more: diarrhea, rectal bleeding, abdominal pain, fever, extraintestinal manifestations, weight loss, or failure to thrive.
• AND
• B) Symptoms on two or more occasions separated by at least 8 weeks or ongoing symptoms of at least 6 weeks duration.
• AND
• C) Endoscopic Findings compatible with UC:
• Superficial inflammation and/or ulceration (involving only the mucosa and submucosa) of the colon, which is continuous from the rectum extending proximally without skip lesions or complete rectal sparing (relative rectal sparing is allowed for patients receiving topical, rectal therapy; patchiness of endoscopic inflammation may be observed in patients with partially treated ulcerative colitis).
• In patients with proctitis or left-sided ulcerative colitis, there may be an area of inflammation in the cecum, usually surrounding the appendiceal orifice.
• No inflammation of the small intestine ("backwash ileitis" is allowed - non-stenotic superficial inflammation of the terminal ileal mucosa associated with severe pancolitis, which resolves following medical or surgical treatment of the colitis).
• No features of Crohn's disease listed above. There is no minimum length of extension of UC required for inclusion in this study.

You may not qualify if…

• Patients will be excluded if they meet any of the following criteria:
• Inability to provide informed consent.
• Non-English speaking.
• Patients presenting for a one-time consultation.

Where it is running

• South Denver Gastroenterology — Denver, Colorado, United States (enrolling)
• AdventHealth — Orlando, Florida, United States (enrolling)
• University of Iowa Health Care — Iowa City, Iowa, United States (enrolling)
• University of Louisville, Clinical Trials Unit — Louisville, Kentucky, United States (enrolling)
• University Of Rochester Medical Center — Rochester, New York, United States (enrolling)
• University of North Carolina — Chapel Hill, North Carolina, United States (enrolling)
• Medical University of South Carolina (MUSC) — Charleston, South Carolina, United States (enrolling)
• Southern Star Research Institute, LLC — San Antonio, Texas, United States (enrolling)
• TIDHI Innovation Inc. — Toronto, Ontario, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.